Lead discovery

InhibOx Announces Scopius-5 – The First 100 Million+ Compound 3D Drug Candidate Design Database

Submitted by InhibOx on 17 December 2010 - 3:33pm

Scopius is the largest available curated 3D compound and fragment database

Oxford, UK, December 17, 2010 - InhibOx Ltd, the specialist in novel and effective computational methods for drug discovery, today announces the launch of Scopius-5 – the world’s largest currently available drug discovery screening database and the first system to pass 100 million compounds. Scopius-5 is a unique and powerful resource that will enable new levels of innovation and rigor to screening processes in drug discovery.

InhibOx Updates Partial Charges for DUD Molecules

Submitted by InhibOx on 6 July 2010 - 9:00pm

Cloud Computing and Drug Discovery article published in Projects Magazine

Submitted by InhibOx on 10 April 2010 - 6:00am

Oxford, UK - 9th April 2010

InhibOx's Paul Finn discusses the potential of on-demand hardware and Software as a Service delivery mechanisms to transform drug discovery research in a recent article for Projects Magazine, a leading research and development publication in the areas of science and technology.

Lead Identification

The InhibOx Applications Team has at its disposal a complete array of technologies to drive structure-, ligand- and fragment-based design approaches, often used in combination to identify diverse sets of novel lead candidates.

AutoDock helps tackle two AIDS targets, HIV Protease and HIV Integrase

Submitted by InhibOx on 8 March 2010 - 7:29pm

Oxford, UK — 11th March, 2010.

The Scripps Research Institute and the FightAIDS@Home project announce new publications and the discovery of two new anti-HIV compounds.

A recent publication in the Journal of Molecular Biology, on which leading InhibOx scientist Dr. Garrett M. Morris is a co-author, describes a dynamic model of HIV integrase inhibition and drug resistance.  This work employed the ligand-protein docking program, AutoDock, of which Garrett is a key developer.

Intelligensys and InhibOx Apply Proven Formulation Approaches to Improve Lead Discovery Efficiency

Submitted by InhibOx on 8 February 2010 - 4:00pm

Oxford and Stokesley, UK — 8th February 2010

InhibOx Ltd (Oxford, UK) and Intelligensys Ltd (Stokesley, North Yorkshire, UK) announce a partnership to apply advanced machine learning approaches, already successful in formulation design, to improve virtual screening and computer-aided drug design (CADD) efficiency.

InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery

Submitted by InhibOx on 3 December 2009 - 4:00pm

Oxford, UK — 3rd December 2009

InhibOx Ltd (Oxford, UK) and MolPort Ltd (Riga, Latvia) announce a strategic partnership to deliver integration in library design and compound provision.

InhibOx collaborates with Lauras AS to advance its drug discovery projects

Submitted by InhibOx on 1 August 2009 - 4:00pm

Oxford, UK - August 2009

InhibOx has undertaken a lead optimization project with Lauras AS, a Norwegian biotechnology company, to help it advance its drug discovery pipeline. Starting from the existing SAR and available structural data, InhibOx used its proprietary virtual screening platform and expertise to derive structural and QSAR models which rationalized the activity of the known leads and identified novel compounds for synthesis. In addition to novelty, these new compounds offer other potential advantages over previously existing leads.

Syndicate content